Review
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virology. Aug 12, 2015; 4(3): 219-244
Published online Aug 12, 2015. doi: 10.5501/wjv.v4.i3.219
Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus
Catalina Méndez, Chantelle L Ahlenstiel, Anthony D Kelleher
Catalina Méndez, Chantelle L Ahlenstiel, Anthony D Kelleher, the Kirby Institute for Infection and Immunity, Wallace Wurth Building-Level 5, Faculty of Medicine, University of New South Wales, Kensington NSW 2052, Australia
Anthony D Kelleher, 2nd St Vincent’s Centre for Applied Medical Research, Darlinghurst NSW 2010, Australia
Author contributions: Méndez C, Ahlenstiel CL and Kelleher AD solely contributed to this paper.
Conflict-of-interest statement: The authors are named inventors on a provisional patent of a short RNA molecule that suppresses HIV-1 infection. Authors declare there are no conflicts of interest among them.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Anthony D Kelleher, MBBS, PhD, Professor, the Kirby Institute for Infection and Immunity, Wallace Wurth Building- Level 5, Faculty of Medicine, University of New South Wales, Kensington NSW 2052, Australia. akelleher@kirby.unsw.edu.au
Telephone: + 61-2-93850182 Fax: +61-2-93850468
Received: December 6, 2014
Peer-review started: December 6, 2014
First decision: December 26, 2014
Revised: January 24, 2015
Accepted: April 27, 2015
Article in press: April 29, 2015
Published online: August 12, 2015
Processing time: 249 Days and 22 Hours
Core Tip

Core tip: The lack of progress in developing an effective human immunodeficiency virus 1 (HIV-1) vaccine has motivated the pressing need for alternate therapies to cure HIV. RNAi therapeutics represent an alternate approach to a functional cure by offering specific targeting of the HIV-1 latent reservoir with the significant advantage of allowing cessation of combination antiretroviral therapy.